About Interius BioTherapeutics

Interius BioTherapeutics develops in vivo lentivector gene therapies specifically targeting B cell lymphomas, utilizing programmable vectors for precise genetic medicine delivery. The company aims to provide effective treatment options for patients with challenging hematological malignancies, addressing the need for targeted therapies in oncology.

```xml <problem> B-cell lymphomas present significant treatment challenges, and there is a need for more targeted therapies to improve patient outcomes. Traditional treatment options may have limited efficacy or significant side effects, highlighting the need for innovative approaches. </problem> <solution> Interius BioTherapeutics is developing in vivo lentivector gene therapies designed for precise genetic medicine delivery, specifically targeting B-cell lymphomas. Their proprietary LENTIVECTOR platform engineers targeted, programmable vectors to deliver genetic medicines directly within the body. This approach aims to provide more effective treatment options for patients with challenging hematological malignancies, offering a new generation of genetic medicines with best-in-class therapeutic potential in oncology and autoimmunity. The company's pipeline includes novel lentivector therapeutics that leverage multidisciplinary knowledge to address unmet medical needs and improve accessibility to advanced therapies. </solution> <features> - Proprietary LENTIVECTOR platform for targeted in vivo gene therapy - Programmable vectors for precision delivery of genetic medicines - Pipeline of novel lentivector therapeutics for oncology and autoimmunity - Focus on in vivo CAR (Chimeric Antigen Receptor) gene therapy for B-cell malignancies - Clinical trials underway for first-in-class in vivo CAR therapeutic </features> <target_audience> The primary target audience includes patients with B-cell malignancies, as well as healthcare providers and clinical researchers focused on innovative cancer therapies. </target_audience> ```

What does Interius BioTherapeutics do?

Where is Interius BioTherapeutics located?

Interius BioTherapeutics is based in Philadelphia, United States.

When was Interius BioTherapeutics founded?

Interius BioTherapeutics was founded in 2019.

How much funding has Interius BioTherapeutics raised?

Interius BioTherapeutics has raised 144570000.

Location

Philadelphia, United States

Founded

2019

Funding

144570000

Employees

59 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Interius BioTherapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

interiusbio.com 3K+

Crunchbase

Founded 2019 – Philadelphia, United States

Funding

Estimated Funding

$100M+

Team (50+)

No team information available.

Company Description

Problem

B-cell lymphomas present significant treatment challenges, and there is a need for more targeted therapies to improve patient outcomes. Traditional treatment options may have limited efficacy or significant side effects, highlighting the need for innovative approaches.

Solution

Interius BioTherapeutics is developing in vivo lentivector gene therapies designed for precise genetic medicine delivery, specifically targeting B-cell lymphomas. Their proprietary LENTIVECTOR platform engineers targeted, programmable vectors to deliver genetic medicines directly within the body. This approach aims to provide more effective treatment options for patients with challenging hematological malignancies, offering a new generation of genetic medicines with best-in-class therapeutic potential in oncology and autoimmunity. The company's pipeline includes novel lentivector therapeutics that leverage multidisciplinary knowledge to address unmet medical needs and improve accessibility to advanced therapies.

Features

Proprietary LENTIVECTOR platform for targeted in vivo gene therapy

Programmable vectors for precision delivery of genetic medicines

Pipeline of novel lentivector therapeutics for oncology and autoimmunity

Focus on in vivo CAR (Chimeric Antigen Receptor) gene therapy for B-cell malignancies

Clinical trials underway for first-in-class in vivo CAR therapeutic

Target Audience

The primary target audience includes patients with B-cell malignancies, as well as healthcare providers and clinical researchers focused on innovative cancer therapies.